Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, Hoang K, Ashley C, McCall D, Rojiani AM, Maria BL, Rixe O, MacDonald TJ, Heeger PS, Mellor AL, Munn DH, Johnson TS.

J Immunother Cancer. 2014 Jul 7;2:21. doi: 10.1186/2051-1426-2-21.

2.

Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.

Schafer CC, Wang Y, Hough KP, Sawant A, Grant SC, Thannickal VJ, Zmijewski J, Ponnazhagan S, Deshane JS.

Oncotarget. 2016 Nov 15;7(46):75407-75424. doi: 10.18632/oncotarget.12249.

3.

Blocking IDO activity to enhance anti-tumor immunity.

Munn DH.

Front Biosci (Elite Ed). 2012 Jan 1;4:734-45. Review.

PMID:
22201909
4.

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.

Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, Albesiano E, Durham NM, Ye X, Tran PT, Tyler B, Wong JW, Brem H, Pardoll DM, Drake CG, Lim M.

PLoS One. 2014 Jul 11;9(7):e101764. doi: 10.1371/journal.pone.0101764.

5.

Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Monjazeb AM, Kent MS, Grossenbacher SK, Mall C, Zamora AE, Mirsoian A, Chen M, Kol A, Shiao SL, Reddy A, Perks JR, T N Culp W, Sparger EE, Canter RJ, Sckisel GD, Murphy WJ.

Clin Cancer Res. 2016 Sep 1;22(17):4328-40. doi: 10.1158/1078-0432.CCR-15-3026.

PMID:
26979392
6.

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS.

Clin Cancer Res. 2012 Nov 15;18(22):6110-21. doi: 10.1158/1078-0432.CCR-12-2130.

7.

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH.

J Clin Invest. 2007 Sep;117(9):2570-82.

8.

Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy.

Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, Lee J, Munn DH.

J Reprod Immunol. 2002 Oct-Nov;57(1-2):143-50. Review.

PMID:
12385839
9.

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH.

PLoS One. 2009 Sep 7;4(9):e6910. doi: 10.1371/journal.pone.0006910.

10.

Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.

Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH.

Nat Immunol. 2001 Jan;2(1):64-8.

PMID:
11135580
11.

Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.

Takamatsu M, Hirata A, Ohtaki H, Hoshi M, Ando T, Ito H, Hatano Y, Tomita H, Kuno T, Saito K, Seishima M, Hara A.

Cancer Sci. 2015 Aug;106(8):1008-15. doi: 10.1111/cas.12705.

12.

Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific.

Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL.

J Reprod Immunol. 2004 Apr;61(2):67-77.

PMID:
15063630
13.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

15.

Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses.

Mellor AL, Munn DH.

J Reprod Immunol. 2001 Oct-Nov;52(1-2):5-13. Review.

PMID:
11600174
16.

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

Soliman H, Mediavilla-Varela M, Antonia S.

Cancer J. 2010 Jul-Aug;16(4):354-9. doi: 10.1097/PPO.0b013e3181eb3343. Review.

17.

IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T cells.

Xie FT, Cao JS, Zhao J, Yu Y, Qi F, Dai XC.

Transpl Immunol. 2015 Oct;33(2):69-77. doi: 10.1016/j.trim.2015.05.003.

PMID:
26002283
18.

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ.

Cancer Immunol Immunother. 2014 Jul;63(7):721-35. doi: 10.1007/s00262-014-1549-4. Review.

19.

Local expression of indoleamine 2,3 dioxygenase in syngeneic fibroblasts significantly prolongs survival of an engineered three-dimensional islet allograft.

Jalili RB, Forouzandeh F, Rezakhanlou AM, Hartwell R, Medina A, Warnock GL, Larijani B, Ghahary A.

Diabetes. 2010 Sep;59(9):2219-27. doi: 10.2337/db09-1560.

20.

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ.

Int J Cancer. 2002 Sep 10;101(2):151-5.

Items per page

Supplemental Content

Support Center